NovaBay Pharmaceuticals (NBY) Names Dr. Mark Andersone as Chief Scientific Officer
More News related to NBY
- NovaBay Pharma (NBY) Posts Q3 Break-Even EPS, 1c Better Than Estimates
- NovaBay Pharmaceuticals Reports Third Quarter Financials and Provides Update on Pipeline of Anti-Infective Compounds
- NovaBay's Aganocides Show Penetration and Efficacy in a Pre-Clinical Infected Human Nail Model of Onychomycosis
- NovaBay to Hold Conference Call to Review Aganocide Data Presented at the Infectious Diseases Society of America Meeting
- NovaBay Pharmaceuticals to Present at 8th Annual Bio Investor Forum 2009 in San Francisco
More News related to Management Changes
- Quicksilver Resources (KWK) Granted Motion for Partial Summary by Texas in BreitBurn (BBEP) Lawsuit
- American International Group (AIG) Implementing Benmosche's Compensation Agreement
- Sun American (SAMB) Receives Listing Rule 5450 Notification from NASDAQ
- Solutia (SOA) To Discontinue Manufacturing at its Plant in Cologne, Germany
- General Dynamics (GD) Business Unit Awarded $2.2B U.S. Army SAC Contract for 724 LAV's
NovaBay Pharmaceuticals, Inc. (NYSE Amex: NBY) has named Mark Anderson, Ph.D. as chief scientific officer, a new position for the company.
Dr. Anderson's credentials include over 17 years of successfully leading research and development programs. He holds numerous patents, patent applications and publications to his credit. Prior to joining NovaBay, he has held senior positions at Myriad Genetics, Elitra Pharmaceuticals, Pfizer-Agouron and Ligand-Glycomed. Dr. Anderson holds a doctorate from Purdue University, and completed postdoctoral studies in chemical biology at Harvard University.
[SM]
Related Categories
Management ChangesStocks Mentioned
-0.03Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
